Protection of melatonin treatment and combination with traditional antibiotics against septic myocardial injury
Background Heart failure is a common complication of sepsis with a high mortality rate. It has been reported that melatonin can attenuate septic injury due to various properties. On the basis of previous reports, this study will further explore the effects and mechanisms of melatonin pretreatment, posttreatment, and combination with antibiotics in the treatment of sepsis and septic myocardial injury. Methods and results Our results showed that melatonin pretreatment showed an obvious protective effect on sepsis and septic myocardial injury, which was related to the attenuation of inflammation and oxidative stress, the improvement of mitochondrial function, the regulation of endoplasmic reticulum stress (ERS), and the activation of the AMPK signaling pathway. In particular, AMPK serves as a key effector for melatonin-initiated myocardial benefits. In addition, melatonin posttreatment also had a certain degree of protection, while its effect was not as remarkable as that of pretreatment. The combination of melatonin and classical antibiotics had a slight but limited effect. RNA-seq detection clarified the cardioprotective mechanism of melatonin. Conclusion Altogether, this study provides a theoretical basis for the application strategy and combination of melatonin in septic myocardial injury..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Cellular & molecular biology letters - 28(2023), 1 vom: 26. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Di, Wencheng [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
Antibiotics |
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s11658-022-00415-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2134712589 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2134712589 | ||
| 003 | DE-627 | ||
| 005 | 20240322175615.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230510s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s11658-022-00415-8 |2 doi | |
| 035 | |a (DE-627)OLC2134712589 | ||
| 035 | |a (DE-He213)s11658-022-00415-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a 42.13 |2 bkl | ||
| 084 | |a 42.15 |2 bkl | ||
| 100 | 1 | |a Di, Wencheng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Protection of melatonin treatment and combination with traditional antibiotics against septic myocardial injury |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background Heart failure is a common complication of sepsis with a high mortality rate. It has been reported that melatonin can attenuate septic injury due to various properties. On the basis of previous reports, this study will further explore the effects and mechanisms of melatonin pretreatment, posttreatment, and combination with antibiotics in the treatment of sepsis and septic myocardial injury. Methods and results Our results showed that melatonin pretreatment showed an obvious protective effect on sepsis and septic myocardial injury, which was related to the attenuation of inflammation and oxidative stress, the improvement of mitochondrial function, the regulation of endoplasmic reticulum stress (ERS), and the activation of the AMPK signaling pathway. In particular, AMPK serves as a key effector for melatonin-initiated myocardial benefits. In addition, melatonin posttreatment also had a certain degree of protection, while its effect was not as remarkable as that of pretreatment. The combination of melatonin and classical antibiotics had a slight but limited effect. RNA-seq detection clarified the cardioprotective mechanism of melatonin. Conclusion Altogether, this study provides a theoretical basis for the application strategy and combination of melatonin in septic myocardial injury. | ||
| 650 | 4 | |a Melatonin | |
| 650 | 4 | |a Septic myocardial injury | |
| 650 | 4 | |a RNA-seq | |
| 650 | 4 | |a Pretreatment | |
| 650 | 4 | |a Posttreatment | |
| 650 | 4 | |a Antibiotics | |
| 700 | 1 | |a Jin, Zhenxiao |4 aut | |
| 700 | 1 | |a Lei, Wangrui |4 aut | |
| 700 | 1 | |a Liu, Qiong |4 aut | |
| 700 | 1 | |a Yang, Wenwen |4 aut | |
| 700 | 1 | |a Zhang, Shaofei |4 aut | |
| 700 | 1 | |a Lu, Chenxi |4 aut | |
| 700 | 1 | |a Xu, Xiaoling |4 aut | |
| 700 | 1 | |a Yang, Yang |0 (orcid)0000-0002-1163-2359 |4 aut | |
| 700 | 1 | |a Zhao, Huadong |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cellular & molecular biology letters |d BioMed Central, 1996 |g 28(2023), 1 vom: 26. Apr. |h Online-Ressource |w (DE-627)363772340 |w (DE-600)2108724-6 |w (DE-576)275076881 |x 1689-1392 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:1 |g day:26 |g month:04 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s11658-022-00415-8 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 936 | b | k | |a 42.13 |j Molekularbiologie |j Molekularbiologie |q VZ |
| 936 | b | k | |a 42.15 |j Zellbiologie |j Zellbiologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 1 |b 26 |c 04 | ||